Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug762 | COVID-19 barrier box Wiki | 1.00 |
| drug3078 | Present Tense Talk (PTT) Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001321 | Autistic Disorder NIH | 0.30 |
| D000067877 | Autism Spectrum Disorder NIH | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000717 | Autism HPO | 0.30 |
| HP:0000729 | Autistic behavior HPO | 0.27 |
Navigate: Correlations HPO
There is one clinical trial.
This study will investigate the acceptability and preliminary effectiveness of training parents to use a structured communication intervention that is aimed towards helping children with autism spectrum disorder (ASD). This intervention has demonstrated benefits for non-autistic children in known areas of difficulty found with autistic individuals. There are currently few evidence-based interventions for school-aged children with ASD who have no other language or intellectual disabilities and are educated in mainstream schools. We will evaluate the benefits of training parents to use a freely available communication technique designed to tackle underlying psychological processes crucial to later development.
Description: The number of participants who dropped out of the trial as a percentage of the total number recruited.
Measure: Trial recruitment feasibility Time: 20 weeks post-trialDescription: Percentage of participants who demonstrate 70% or more of intervention behaviours during the training roleplay assessment.
Measure: Feasibility of training procedures Time: BaselineDescription: Change to caregiver reminiscing style ratio following training
Measure: Training enactment Time: Change from baseline to 20 weeks post-trialDescription: The actual number of intervention behaviours caregivers demonstrate during conversations at post-trial.
Measure: Implementation fidelity (actual dosage) Time: 20 weeks post-trialDescription: The mean number of intervention minutes delivered by caregivers
Measure: Implementation fidelity (frequency of intervention delivery) Time: 20 weeks post-trialDescription: A qualitative analysis (guided by the Theoretical Framework of Acceptability) of post-trial caregiver interviews to determine caregiver acceptability of the ER intervention.
Measure: Intervention acceptability Time: 20 weeks post-trialDescription: Change to child scores on the California Verbal Learning Test for Children (CVLT-C)
Measure: Memory test Time: Change from baseline to 20 weeks post-trialDescription: Number of child memory elaborations during parent-child conversations
Measure: Memory elaborations Time: Change from baseline to 20 weeks post-trialDescription: Change to child scores on the Theory of Mind Battery
Measure: Mental state understanding Time: Change from baseline to 20 weeks post-trialDescription: Change to child scores on the Self-Description Questionnaire
Measure: Self-concept Time: Change from baseline to 20 weeks post-trialAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports